Bradley Dean Tait from 80 Christian Way, North Andover, MA 01845, age 65, Phone: (734)3584001

Name / Title

Company / Classification

Phones & Addresses

Bradley Dean Tait
Real property

BRAD TAIT ENTERPRISE LLC

22 Bartlett St, Malden, MA 02148

Resumes

Vice President - Medicinal And Process Chemistry

view source

Location:

Pasadena, CA

Industry:

Pharmaceuticals

Work:

Brad Tait Enterprise Nov 2014 - Dec 2016
Pharmaceutical Consulting
Frequency Therapeutics Nov 2014 - Dec 2016
Vice President - Medicinal and Process Chemistry
Proteostasis Therapeutics, Inc. Nov 2008 - Nov 2014
Vice President - Chemistry and Cystic Fibrosis Leader
Pfizer Oct 2003 - Oct 2007
Senior Director - Cardiovascular and Atherosclerosis Chemistry and Pet and Psl
Pfizer Jul 2003 - Oct 2003
Director - Cns Chemistry

Education:

Yale University 1986 - 1987
Wayne State University 1981 - 1986
Doctorates, Doctor of Philosophy, Organic Chemistry Andrews University 1978 - 1981
Bachelors, Bachelor of Science, Chemistry Florida Institute of Technology
Bachelors, Bachelor of Science

Skills:

Drug Discovery
Medicinal Chemistry
Chemistry
Drug Design
Organic Chemistry
Cro
Parallel Synthesis
Drug Metabolism
Organic Synthesis
Infectious Diseases
Lead Change
Inflammation
Science
Adme
Gpcrs

Vp Of Chemistry At Proteostasis Therapeutics Inc

view source

Location:

Greater Boston Area

Industry:

Pharmaceuticals

Us Patents

Hiv Protease Inhibitors
view source
US Patent:

6512006, Jan 28, 2003
Filed:

Aug 17, 2000
Appl. No.:

09/641260
Inventors:

John Michael Domagala - Canton MI
Edmund Lee Ellsworth - Brighton MI
Christopher Andrew Gajda - Ann Arbor MI
Elizabeth Ann Lunney - Ann Arbor MI
Alexander Pavlovsky - Ann Arbor MI
Vara Prasad Venkata Nagendra Josyula - Ann Arbor MI
Bradley Dean Tait - Killingworth CT
Assignee:

Warner-Lambert Company - Ann Arbor MI
International Classification:

C07D30930
US Classification:

514460, 546192, 549292
Abstract:

The present invention related to novel dihydropyrones possessing 3-position nitrogen atom, which inhabit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections, and diseases, including AIDS.

Hiv Protease Inhibitors
view source
US Patent:

6528510, Mar 4, 2003
Filed:

Nov 2, 2000
Appl. No.:

09/674652
Inventors:

John Michael Domagala - Canton MI
Edmund Lee Ellsworth - Brighton MI
Christopher Andrew Gajda - Ann Arbor MI
Susan Elizabeth Hagen - Canton Township MI
Michael James Lovdahl - Ann Arbor MI
Elizabeth Ann Lunney - Ann Arbor MI
Larry James Markoski - Champaign IL
Josyula Venkata Nagendra Vara Prasad - Ann Arbor MI
Bradley Dean Tait - Canton MI
Assignee:

Warner-Lambert Company - Morris Plains NJ
International Classification:

A61K 31495
US Classification:

51425201, 5142275, 5142521, 514256, 514269, 514314, 514397, 544 60, 544298, 544315, 544374, 546 1, 546268, 5483044, 5483047, 5483111, 549 29, 549292, 549417
Abstract:

The present invention relates to novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of the dihydropyrones and intermediates useful in the preparation of the final compounds.

Hiv Protease Inhibitors
view source
US Patent:

6852711, Feb 8, 2005
Filed:

Nov 19, 2002
Appl. No.:

10/299510
Inventors:

John Michael Domagala - Canton MI, US
Edmund Lee Ellsworth - Brighton MI, US
Christopher Andrew Gajda - Ann Arbor MI, US
Susan Elizabeth Hagen - Canton Township MI, US
Michael James Lovdahl - Ann Arbor MI, US
Elizabeth Ann Lunney - Ann Arbor MI, US
Larry James Markoski - Champaign IL, US
Josyula Venkata Nagendra Vara Prasad - Ann Arbor MI, US
Bradley Dean Tait - Canton MI, US
Assignee:

Agouron Pharmaceuticals, Inc. - San Diego CA
International Classification:

A61K031/33
A61K031/35
C07D277/00
C07D309/00
C07D315/00
US Classification:

514183, 514359, 514367, 514393, 514412, 514415, 514451, 514460, 548152, 548169, 548178, 5483044, 548509, 549 29, 549292, 549417
Abstract:

The present invention relates to novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of the dihydropyrones and intermediates useful in the preparation of the final compounds.

Hiv Protease Inhibitors
view source
US Patent:

6927217, Aug 9, 2005
Filed:

Oct 16, 2002
Appl. No.:

10/271467
Inventors:

John Michael Domagala - Canton MI, US
Edmund Lee Ellsworth - Brighton MI, US
Christopher Andrew Gajda - Ann Arbor MI, US
Elizabeth Ann Lunney - Ann Arbor MI, US
Alexander Pavlovsky - Ann Arbor MI, US
Vara Prasad Venkata Nagendra Josyula - Ann Arbor MI, US
Bradley Dean Tait - Killingworth CT, US
Assignee:

Warner-Lambert Company - Ann Arbor MI
International Classification:

C07D401/06
C07D401/04
C07D403/04
A61K031/351
US Classification:

5142278, 5142315, 51425201, 5142541, 514256, 514326, 514336, 514367, 514365, 514372, 514378, 514381, 514383, 514393, 514406, 514444, 514451, 544 60, 544149, 544238, 544333, 544374, 544405, 5462844, 546192, 548152, 548215, 548240, 548255, 5482672, 548254, 5483641, 549 60, 549292
Abstract:

The present invention relates to novel dihydropyrones of Formula I wherein X is NH or NR, which inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS.

Hiv Protease Inhibitors
view source
US Patent:

20050075390, Apr 7, 2005
Filed:

Sep 9, 2004
Appl. No.:

10/938442
Inventors:

Frederick Boyer - Canton Township MI, US
John Domagala - Canton MI, US
Edmund Ellsworth - Brighton MI, US
Christopher Gajda - Ann Arbor MI, US
Susan Hagen - Canton Township MI, US
Michael Lovdahl - Ann Arbor MI, US
Elizabeth Lunney - Ann Arbor MI, US
Larry Markoski - Champaign IL, US
Josyula Venkata Prasad - Ann Arbor MI, US
Bradley Tait - Canton MI, US
International Classification:

C07D309/30
A61K031/366
US Classification:

514460000, 514459000, 549293000
Abstract:

The present invention relates to novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of the dihydropyrones and intermediates useful in the preparation of the final compounds.

Proteostasis Regulators
view source
US Patent:

20120214824, Aug 23, 2012
Filed:

Dec 8, 2011
Appl. No.:

13/315057
Inventors:

Bradley Tait - Malden MA, US
Christopher Borella - Bedford MA, US
Robert Chambers - Charlestown MA, US
Matthew Cullen - Braintree MA, US
International Classification:

A61K 31/519
A61K 31/47
A61K 31/4709
A61K 31/4162
A61P 3/10
C07D 491/052
C07D 409/08
A61P 35/00
A61P 25/28
A61P 25/16
A61K 31/436
C07D 471/04
US Classification:

514257, 5142641, 514302, 514311, 514314, 514406, 544247, 544279, 546116, 546165, 5483605
Abstract:

The present invention is directed to compounds of Formulae (I), (II), (III), (IV), (V), (VI), (VII), and (VIII), pharmaceutical compositions thereof and methods of use thereof in the treatment of conditions associated with a dysfunction in proteostasis.

Proteostasis Regulators
view source
US Patent:

20120316193, Dec 13, 2012
Filed:

May 10, 2012
Appl. No.:

13/468757
Inventors:

Megan Foley - Cambridge MA, US
Bradley Tait - Malden MA, US
Matthew Cullen - Braintree MA, US
International Classification:

C07D 207/333
C07D 401/06
C07D 403/06
C07D 471/04
C07D 405/06
C07D 231/12
C07D 413/06
C07D 417/06
C07D 409/06
C07D 207/34
A61K 31/402
A61K 31/454
A61K 31/4025
A61K 31/4178
A61K 31/4745
A61K 31/404
A61K 31/4155
A61K 31/415
A61K 31/4535
A61K 31/4192
A61P 25/28
A61P 25/16
A61P 25/00
A61P 3/10
A61P 35/00
C07D 207/337
US Classification:

514294, 548540, 546208, 548518, 5483147, 546 94, 548517, 548468, 546211, 5483641, 5483741, 546209, 546213, 548255, 544372, 544360, 548561, 546201, 514423, 514326, 514422, 514397, 514414, 514323, 514406, 514359, 514427
Abstract:

The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds.

Compounds For Treating Protein Folding Disorders
view source
US Patent:

20130072473, Mar 21, 2013
Filed:

May 9, 2012
Appl. No.:

13/467949
Inventors:

Bradley Tait - Malden MA, US
Noel A. Powell - Westford MA, US
Matthew Cullen - Braintree MA, US
International Classification:

A61K 31/55
C07D 495/04
C07D 333/68
C07D 417/04
C07D 307/85
A61K 31/4743
A61K 31/4745
US Classification:

514215, 514301, 546114, 514367, 548159, 540593, 514310, 546143, 514470, 549467, 514443, 549 57
Abstract:

The present invention is directed to compounds of Formulae (I), (IIa-IIh), (IIIa-IIIe), (IVa-IVc), (Va-V1), (VIa-VII), (VII), (VIII) and (IX), pharmaceutical compositions thereof and methods of use thereof in the treatment of conditions associated with a dysfunction in proteostasis.